CoreAge Rx vs HealthSource
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and HealthSource head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 79 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
That doesn't make HealthSource a bad call — it's best for readers who want compounded semaglutide or tirzepatide (injection or oral) in all 50 states from $199/mo. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | HealthSource | |
|---|---|---|
| Brief Score | 94/100 (A) | 79/100 (C) |
| Semaglutide | $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published | From $199/mo (all doses, compounded) |
| Tirzepatide | $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published | From $299/mo (all doses, compounded) |
| Coverage | US only; restrictions by state, confirmed at intake | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.
HealthSource: New to the tracker on 1 August 2026. The published line reads From $199/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.